Compare Credo Technology Group Holding Ltd (CRDO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Sanofi SA — how do they compare? Credo Technology Group Holding Ltd trades at $216.27 (market cap $39.82B), while Sanofi SA trades at $40.14 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 2.4× Credo Technology Group Holding Ltd's market cap, and Sanofi SA pays a 6.01% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Sanofi SA for 94 Days on average.
| CRDO | SNY | |
|---|---|---|
Market Cap | $39.82B | $95.18B |
Volume | 9,451,558 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $302.52 | $52.34 |
52-Week Low | $87.81 | $39.51 |
Typical Hold Time | 22 Days | 94 Days |
Enterprise Value | $39.08B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $212.42, down 3.45% today but maintains strong technical support near $204 with bullish moving averages. The company demonstrates exceptional fundamentals with 114.7% YoY revenue growth (Seeking Alpha, 2026-09-25) and 33.83% net margins, though valuation remains elevated at P/E of 74.6. Recent earnings beats and AI infrastructure demand drive positive sentiment.
Outlook remains positive given triple-digit revenue growth and $267.33 analyst price target (87.5% buy ratings), but premium valuation and customer concentration pose risks. The stock offers exposure to AI connectivity chip demand with potential for 26% upside to consensus target, though execution risks require monitoring.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
